25/08/2026 Spyre Therapeutics announced topline results from the RA Sub-study of the Phase 2 SKYWAY trial of SPY072 Spyre Therapeutics announced topline results from the RA Sub-study of the Phase 2 SKYWAY trial of SPY072 (Ref) Spyre Therapeutics announced topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2, SKYWAY-RD/ NCT07148414 basket trial evaluating SPY072 (Anti-TL1A) in rheumatic diseases. Both the doses of SPY072 demonstrated statistically signif

03/06/2026 Johnson & Johnson late-breaking results showed nipocalimab significantly reduced SLE disease activity in a Phase 2 study Johnson & Johnson announced biomarker exploratory analyses from a Phase 2 study of nipocalimab in moderate-to-severe SjD Argenx presented efgartigimod data showing long-term sustained patient benefit in myositis and SjD at EULAR-2026 JJP Biologics announces positive interim Phase 1b data for nebaprubart in Linear IgA Disease Spyre Therapeutics an